API

Refarmed Chemicals presents Emedastine Difumarate, an exemplary antihistamine pharmaceutical agent meticulously designed to grant symptomatic relief for individuals battling allergic conjunctivitis. As a testament to its efficacy, Emedastine Difumarate operates as a selective blocker of histamine H1 receptors, adeptly preventing the histamine-induced dilation of blood vessels and curbing mast cell degranulation. Crafted as an ophthalmic solution, the medicine should be administered with precision—1 drop into each affected eye, twice daily—to ensure optimal results. The product is characterized by its white to yellowish powder form, testament to its purity and the high standards of manufacturing. Typically soluble in water and sparsely soluble in anhydrous ethanol, the product maintains a clean and uncolored appearance in the solution with a pH range carefully maintained between 3.0 to 4.5. In compliance with rigorous industry standards, Emedastine Difumarate proudly bears EU GMP certification, guaranteeing its production under the highest quality management protocols. Furthermore, it is crucial to note that the product is strictly contraindicated for individuals with known hypersensitivity to its components and should be avoided by those with narrow-angle glaucoma. Utilization of Emedastine Difumarate may lead to temporary blurred vision and other minor visual disturbances; hence, caution is advised while engaging in tasks necessitating sharp vision post-application. Moreover, it's celebrated for its well-tolerated nature, with minimal side effects, predominantly confined to the ocular region such as itching or burning sensations, and less commonly systemic effects like headache or fatigue. Our product ensures a safe storage parameter within room temperature (20-25°C) and gives due attention to light protection, thereby maintaining its integrity. With Emedastine Difumarate, Refarmed Chemicals delivers an established, profound solution for alleviation from the discomfort caused by allergic conjunctivitis, steering toward better ocular health for patients worldwide.

Products still subject to third-party patent protection might be available solely for R&D purposes.

APIXABAN is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.

Products still subject to third-party patent protection might be available solely for R&D purposes.

TERBINAFINE HCL is an antifungal medication used to treat pityriasis versicolor, fungal nail infections, and ringworm, including jock itch and athlete's foot.

Products still subject to third-party patent protection might be available solely for R&D purposes.

RACECADOTRIL is an antidiarrheal medication which acts as a peripheral enkephalinase inhibitor. RACECADOTRIL has an antisecretory effect - it reduces the secretion of water and electrolytes into the intestine.

Products still subject to third-party patent protection might be available solely for R&D purposes.